Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

NCT01785771 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.

NCT NCT01785771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01785771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c
Lead sponsor
Intarcia Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2013
Completion date
January 31, 2018
Enrollment
100 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes